Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...

The majority of people with advanced EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line osimertinib ...

抗表皮生长因子受体（EGFR）单抗是重要的肿瘤治疗药物，通过特异性抑制 EGFR 下游信号通路发挥抗肿瘤效应，在 RAS/BRAF 野生型的转移性结直肠癌（mCRC）、非小细胞肺癌（NSCLC）中应用广泛。然而，有研究显示超过 80% 的患者使用抗 ...

Concerns about COVID-19 have significantly diminished, but researchers continue to analyze its high transmission rate, aiming ...

EGFR（表皮生长因子受体）靶向药物是我们在临床上最常见、也是应用最广泛的的靶向药物。抗 EGFR ...

That means they’re the main cause of your cancer growth and cell division. Epidermal growth factor receptor (EGFR) mutation is one biomarker doctors look for during testing. EGFR is a protein on ...

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its partner Betta Pharmaceuticals ...

For children with vesicoureteral reflux, recurrent urinary tract infections (UTIs) are associated with a decrease in ...

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...

10月31日，迪哲医药发布了2024年的三季度业绩。今年前三季度，迪哲医药营收达到3.38亿元，同比增长743.97%，公司亏损缩减32.63%，达到5.58亿元。